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Abstract
The innate and adaptive immune systems have evolved together to fight infection and cancerous tissues. The
innate immune system emerges first with the adaptive immune system following, both ostensibly being bridged
by dendritic cells (DC). Recently cells have emerged that possess characteristics of both innate and adaptive immune
cell qualities, termed interferon-producing killer dendritic cells (IKDCs). These cells have an indistinct origin that is
not well understood. They appear to have more NK cell attributes than DC but purportedly can regulate the immune
system similar to immunoregulatory NK cells. Because of this, they have been renamed pre-mNK cells (pre-mature NK
cells). We argue in this commentary that pre-mNK cells may contribute to cancer recurrence.
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Introduction
Pre-mature Natural Killer cells (pre-mNK) are murine
hybrid cells with characteristics of both NK cells and
DC, defined by markers CD11c+CD49b+B220+NK1.1
+NKG2D+GR-1− and expressing MHC class II upon acti-
vation [1–4] (Fig. 1). Originally called IKDC, these cells
were first characterized in 2006 [1, 5, 6], but since then
have been recognized to more closely resemble NK cells
rather than DC or plasmacytoid DCs (pDCs) [7, 8].
Specifically, pre-mNK cells resemble an immature NK,
before the cell begins to express CD27, and have clas-
sical attributes of cellular immaturity such as immature
cell morphology, expression of Ly108, and low amounts
of CD43. These cells also are dependent on the Id-2
transcription factor, which has been shown to inhibit
pDC differentiation [9]. Once these cells begin to ex-
press CD27, they stop expressing the pre-mNK marker
B220 and their function changes, commonly from that
of a pre-mNK cell to that of a mature NK (mNK) cell
[6–8, 10]. Little is known about the formation or
differentiation of these cells, but their development is
IL-15 dependent [2, 4, 11], and appears to depend on
their environment in which they reside and become acti-
vated [6, 12]. Below we discuss their implications in
tolerance to tumors both in mice and humans.
Murine pre-mNK cells
Initially, murine pre-mNK cells were described in mice
to have anti-tumor properties [5, 6]. However, subse-
quent studies, including our own data, have shown that
depletion of NK1.1+ cells leads to enhanced tumor rejec-
tion, viral clearance, and decreased exhaustion of T cells
[13–19]. Surprisingly most of the studies that depleted
NK1.1+ cells failed to show that pre-mNK cells were also
being depleted [11]. These findings seem to contradict
the anti-tumor, cytotoxic role of these cells. One recent
study showed that activated pre-mNK cells prevented
autoimmunity through PD-L1 and IL-10 [20]. Therefore,
it seems that the natural predilection for pre-mNK cells
is to suppress autoimmunity. We hypothesize that this
attribute of pre-mNK cells contributes to tumor
recurrence.
The role of pre-mNK cells in the context of immuno-
therapy using adoptive cell transfer (ACT) of T cells has
not been studied. Pre-mNK cells have mainly been used
in isolation as tumor killers or in the context of non-self
tumor-antigens such as OVA. These non-self antigens
activate high affinity T cells that were not educated for
OVA in the thymus, and as a result, Treg cells to OVA
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do not exist [21]. This may confound the natural activity
of pre-mNK cells which is to suppress tumor-antigens
that are also self-antigens.
Previously, we have shown that CD4+ T cells specific for
a tumor-associated self-antigen (TAA) called tyrosinase-
related protein 1 (TRP-1), a melanoma differentiation
antigen (MDA), can treat large established tumors by
direct killing of cancerous cells [16]. We found that lym-
phopenia (either induced before adoptive transfer or nat-
urally occurring in RAG−/− mice) enhanced rejection of
tumors through loss of regulatory elements such as Treg
cells and MDSCs [22] or through increased homeostatic
cytokines that could potentially help T cells attack tumors
better [23, 24]. Nevertheless, about 50 % of the tumors
would recur locally [23, 24]. Surprisingly, cancer recur-
rence was diminished considerably when NK1.1+ cells
were depleted with PK-136 depleting antibodies. In
addition, depletion of NK1.1+ cells increased autoimmune
vitiligo, serum inflammatory cytokines, and chemokines
[11]. This was thought to be due to the absence of NK cell
“cytokine sinks,” [22] thus enhancing the cytotoxicity of
the CD4+ T cells through increased availability of IL-2 and
possibly IL-15. However, depletion of NK cells with NK
cell-specific antibody, called asialo-GM1, failed to fully
duplicate the results from experiments employing
NK1.1+ cell depletion [11]. Furthermore, we showed
that B220+ cell depletion but not asialo-GM1+ cell
depletion was similar to the depletion of NK1.1+ cells,
suggesting that B220+NK1.1+ pre-mNK cells were
playing a role in dampening the CD4+ anti-tumor re-
sponse in our preclinical model of melanoma [11].
These data made us question the purported role of
pre-mNK cells in cancer biology.
Since 2006, the role of pre-mNK in the tumor set-
ting has been equivocal. Taieb et al. first described
that treating melanoma with Imatinib and IL-2 re-
sulted in pre-mNKs expanding in the spleen, produ-
cing copious IFN-γ, and killing tumor cells via TRAIL
[5]. Although the tumor microenvironment affects the
function of pre-mNK [8], only our group studied pre-
mNK cells without ex vivo pre-activation, calling into
question the anti-tumor role of pre-mNK cells in the
natural course of the disease [11]. We suggest, as
others have implicated, that pre-mNK cells must be
licensed by tumor cells through NKG2D or other
ligands to become activated [3, 21]. This leads to
their maturation into functional APCs through upreg-
ulation of MHC class II and other receptors, and
their migration into draining lymph nodes where they
present tumor-self antigens to self-reactive T cells
which are tolerized or programmed to become Treg cells
rather than activated effector cells. Experiments by others
using blocking antibodies to NKG2D decreased the activa-
tion of OTII cells by OVA expressing B16-Rae1 cells [21],
suggesting that if licensing cannot occur by tumor cells,
pre-mNK cells cannot interact with T cells through MHC
class II. Licensing occurs to allow pre-mNK cells to kill
tumor cells initially so that they may acquire tumor anti-
gen for presentation, occurring in less than 48–72 h as
shown by migration experiments [3]. This is temporary
and results only in delay of tumor growth [3]. We suggest
that this licensing could be mistaken for tumor killing.
Fig. 1 Comparison between the immune-related molecules expressed on murine pre-mNK cells and human CD56bright HLA-DR+ NK cells. Murine
pre-mNK cells classically express CD11cloCD49bB220NK1.1 and are GR-1neg in C57BL6/mice, but lack NK1.1 in other strains. Pre-mNK cells also express
NKG2D and respond to the chemokine CCL2 due to expression of CCR2, making them apt for migrating to tumor sites. Upon licensing by tumor cells,
pre-mNK cells express class II and other immune related molecules. The Id-2 transcription factor is prevalent in pre-mNK cells showing that they are
more NK cell-like than DC. Both murine and human CD56brightHLA-DR+ NK cells express the IL-2/IL-15Rβγ, making them responsive to these cytokines
in different contexts. Human CD56brightHLA-DR+ NK cells express CD56 at high levels, HLA-DR, and CD94/NKG2 receptors, and low to no amounts
CD16. They are CXCR3 expressing cells making them able to migrate to secondary lymphatic tissues or places of inflammation. Both murine and
humans cells may also express PD-L1 in different environmental conditions, and both can make IFN-γ and IL-10 in varying amounts, again depending
on their environment. By no means are these molecules listed complete or absolute and further research is needed to clarify the roles of each on
these cells
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Although pre-mNK cells were first described for their
role in anti-tumor immunity, they have been described
as controlling tolerance to self-antigens [20]. These cells
prevent autoimmunity or reduce the severity of auto-
immune conditions such as experimental autoimmune
encephalitis (EAE) [4, 17]. Melanoma has also been
shown to license NK1.1+B220+CD11c+MHC class II+
pre-mNK cells to present tumor antigens [3, 21]. Pre-
mNK cells also express the inhibitory PD-1 ligand
(PD-L1) [12, 20, 21] and can make the immunosup-
pressive cytokine, IL-10 [20]. PD-L1 has clearly been
shown in pre-clinical [25–28] and clinical scenarios to in-
hibit tumor immunity through adaptive resistance mecha-
nisms [29, 30] as well as to be involved in controlling
chronic infections and autoimmunity [31–35]. Thus pre-
mNK cells expressing PD-L1 could potentially suppress
immunity to cancer, like cancer cells themselves. Because
melanoma can expresses TRP-1, a melanocyte differenti-
ation antigen expressed in the skin that is targeted by our
TRP-1 specific CD4+ T cells, autoimmunity can ensue.
Therefore, pre-mNK cells might be involved in tolerance
rather than immunity during an immune response to mel-
anoma. This is demonstrated in our recent work showing
that autoimmune vitiligo is increased in tumor-bearing
mice treated with CD4+ T cells specific for TRP-1 and
antibodies to deplete NK1.1+ cells [11].
Like NK cells, pre-mNK cells are IL-15 dependent [1].
It has been shown that production of hIL-15 by in vivo
gene transfer in mice increases pre-mNK cell numbers
and function [36]. On the contrary, IL-15−/−RAG−/− and
IL-2Rγ−/−RAG−/− mice both lack NK and pre-mNK cells
[4, 7, 11]. Consistent with this, we have shown that
tumor rejection is enhanced in IL-15−/−RAG−/− mice
and that recurrence of melanoma is less when compared
to IL-15 wild type controls [11]. In line with this data, it
has been shown that pre-mNK cells are low in auto-
immune prone NOD mice, which are susceptible to dia-
betes due to genetic mutations linked to the distal end
of chromosome 7 [37]. If the distal end of chromosome
7 is modified to express WT genes as in NOD-Lc7 mice,
they are not prone to diabetes, and have restored num-
bers of pre-mNK cells [1]. This suggests that the natural
tendency of pre-mNK cells is to cause suppression
rather than immunity in vivo.
Pre-mNK cell function modulates over the course of
an immune response. After stimulation, presumably
through NKG2D and other ligands, pre-mNK cells first
acquire lytic activity, signaling through classical NK re-
ceptors such as NKG2D, and killing through NKG2D
and TRAIL [3, 6, 10]. They then produce IFN-γ, and in-
crease expression of MHC-II and migrate via chemokine
receptors to the secondary lymphatic tissue [6, 10]. In
the tumor microenvironment, direct contact with the
tumor cell provides this stimulation, leading not only to
MHC-II expression and IFN-γ production, but also to
IFN-γ-induced PD-L1 expression [8, 12, 21, 30]. We sug-
gest that this adaptive immune response induces exhaus-
tion and increases Treg cells, suppressing T cell function.
Because the tumor cell itself licenses pre-mNK cells for
antigen presentation, the antigens encountered are likely
to be self-antigens [3, 21]. Thus, in untreated cancer,
unmanipulated pre-mNK cells may act to protect the
host by dampening the immune response — beneficial
in autoimmunity, but detrimental in cancer or chronic
infections [20]. However, experimentally manipulated
pre-mNK cells, those which are mostly studied up to
this point, may actually activate the immune response
because treatment-induced cellular trauma makes
more DAMPs available, thus confounding their nat-
ural role [1, 3–7, 21].
Human pre-mNK cells
The closest pre-mNK analog in humans is the CD56bright
NK cell [38] or the HLA-DR+ NK cell, which is a subset
of CD56bright NK cells [39]. Here, we will refer to the hu-
man equivalent as CD56brightHLA-DR+ NK cells because
these cells expand only from HLA-DR+ NK cell popula-
tions and can present antigen [39]. However, we will also
refer to CD56bright cells alone when discussing literature
pertaining only to them and try to draw out similarities
between CD56bright, CD56brightHLA-DR+ NK cells, and
mouse pre-mNK cells. Our goal is to suggest that pre-
mNK cells in humans are CD56bright HLA-DR+ NK cells.
Like pre-mNK cells, CD56bright NK cells are recog-
nized as an immunoregulatory NK subset in humans
[40–42], and are defined by the markers CD3−CD56
+CD16dimHLA-DR+ [38, 39, 42–45] (Fig. 1). Like pre-
mNK cells they represent a small subset of total NK
cells, approximately less than 10 % of CD56+ cells [42].
In their regulatory role, they lyse CD4+ T cells via TRAIL
and NKG2D, and secrete large amounts of IFN-γ and
regulatory cytokines [41, 45, 46]. Like pre-mNK cells,
CD56bright NK cells are dependent on IL-15 for develop-
ment and activation [42–44], and are implicated in control-
ling autoimmunity and mediating the immune response to
cancer and viral infections. In non-pathologic physiology,
CD56bright NK cells maintain fetal tolerance by inhibiting
Th-17-mediated immune responses at the maternal-fetal
interface [47].
HLA-DR+ NK cells also expand to IL-15 and high
doses of IL-2 [39]. However, these types of experimental
systems used to study these cells in vitro, we would
argue, can be highly non-physiologic and may drive
HLA-DR+ NK cells to a cytotoxic phenotype, leading to
large amounts of IFN-γ secretion. However, their physio-
logical role in vivo without external activation may in-
volve tolerance mechanisms as these cells are seen at
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sites of inflammation, cancer, and at the maternal-fetal
interface [47–52].
Solid tumors have large populations of CD56bright NK
cells at the primary tumor bed and at metastases, and
similarly to pre-mNK, they expand following treatment
[48–52]. As tumors progress or metastasize, CD56bright
NK cells remain present in the primary bed, at the
metastases, and in lymph tissue, but lose function or
become inactive despite high expression levels of perforin
and HLA-DR [50, 53, 54]. These cells we hypothesize are
CD56+HLA-DR+NK cells mentioned above that have
induced tolerance to tumor.
CD56bright NK cells have lytic activity via TRAIL, and
when activated, upregulate HLA-DR and IFN-γ produc-
tion to present antigen and modulate the immune re-
sponse, either productively or pathologically [55]. This
may be similar to pre-mNK cell activation through
NKG2D ligands on murine tumors, allowing them to
present antigen once it is acquired [3]. Although they
can be lytic, it also has been shown that in both the viral
and the autoimmune setting that CD56bright NK cells
control CD4+ T cell activity by expressing high levels of
CD39/73 and CD38, using adenosine as a modulator of
T cell activity. Stelma et al. report that after HBV treat-
ment and improved ALT, the host’s CD56bright NK cells
express high levels of CD38, attenuating the chronic
pathologic immune response [55]. Morandi et al.
report that CD38 inhibition increases Juvenile Idio-
pathic Arthritis (JIA) severity, while the CD38 enzyme
expressed by CD56bright NK cells in patients with
active JIA has attenuated function [56].
Conclusion
CD56bright HLA-DR+ immunoregulatory NK cells are
potentially the human analog of the contentious murine
pre-mNK cell. These highly proliferative cells, though a
small population in both species, can readily expand to
regulate the immune response, acting through direct
cytolysis, cytokines, and metabolic signals, and acting as
antigen-presenting cells with the capability to activate or
terminate an immune response. These cells in human
and mouse clearly stifle immune activity in autoimmun-
ity and pregnancy. Their role in chronic pathology is
more complex. Acting through cytolysis and/or antigen-
presentation, CD56bright HLA-DR+ NK or pre-mNK cells
may dampen the response to chronic low-level stimula-
tion or self-antigen, for instance during established
melanoma, but they activate a response under acute
conditions of treatment-induced DAMPs, high-level
PAMP stimulation, or high doses of γc-cytokines such as
IL-2 or IL-15. Thus, pre-mNK or CD56bright HLA-DR+
NK cells have the potential to be exploited therapeutic-
ally, but their opposing roles in differing immune envir-
onmental milieus must be taken into consideration.
CD56bright cells and murine counterpart pre-mNK
cells represent potential targets for immunotherapies,
whether to suppress the immune system to prevent
autoimmune diseases, or to enhance the immune system
to treat cancer. It is clear that more research is needed
to fully elucidate the role of these cells during an
immune response in human disease.
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